Quarterly report · Q1
4587.TEDINET S100QQKF
Period2023-01-01 → 2023-03-31
Filed2023-05-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Amended by S100S6T6 (2023-11-09).
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.0bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥26.9bn | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥420m | 2022-01-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Operating income | −¥267m | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | −¥1.2bn | 2022-01-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥400m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥6.7bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥1.1bn | 2022-01-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥249m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥7.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥829m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥249m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥7.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥829m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥59.8bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥63.9bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥52.9bn | at 2022-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥28.0bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥31.8bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥31.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥32.0bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥24.7bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥25.4bn | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥31.8bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥32.0bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥24.7bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥11.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥5.2bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥10.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥7.7bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥83m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥8m | 2022-01-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥381m | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥27.4bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥23.7bn | 2022-01-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥1.1bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥20.8bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥22.2bn | 2022-01-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-1.92 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥58.19 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-6.39 | 2022-01-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-1.92 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥58.14 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-6.39 | 2022-01-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 53.2% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 46.6% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 13
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥3m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥978m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥978m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥381m |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥4.0bn |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥4.0bn |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥3m |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥136m |
| —segment total | revenue | 2023-01-01 → 2023-03-31 | ¥5.0bn |
| —segment total | revenue external | 2023-01-01 → 2023-03-31 | ¥5.0bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥3m |
| —segment total | segment profit | 2023-01-01 → 2023-03-31 | −¥244m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 486
| Item | Context | Value | Unit |
|---|---|---|---|
| Company name cover page | FilingDateInstant | Original text (Japanese)ペプチドリーム株式会社 | |
| Company name in english cover page | FilingDateInstant | PeptiDream Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長CEO リード・パトリック | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番23号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 044(270)1300 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)ＩＲ広報部ディレクター 沖本 優子 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番23号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 044(223)6612 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)ＩＲ広報部ディレクター 沖本 優子 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E27486 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45870 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ペプチドリーム株式会社 | |
| Filer name in english | FilingDateInstant | PeptiDream Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Current period end date | FilingDateInstant | 2023-03-31 | |
| Type of current period | FilingDateInstant | Q1 | |
| Current fiscal year end date | FilingDateInstant | 2023-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-01-01 | |
| Comparative period end date | FilingDateInstant | 2022-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2022-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Text · Plus | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |